Project description
AI solution to help prevent infections acquired in hospitals
Every year, about 4.1 million Europeans pick up infections during their hospital stay. These hospital-acquired infections are caused by specific bacterial subspecies, whose identification is significantly hampered by time and cost factors. To address this issue, Spanish company CLOVER Bioanalytical Software used AI to develop algorithms and further improve an effective technology called matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS). The EU-funded ArtIST project will find, develop and commercialise solutions to quickly and economically identify bacteria’s resistance processes in clinically relevant subspecies. Moreover, it will carry out a feasibility study in preparation for clinical validation and for entering the market.
Objective
Specific bacterial subspecies, often resistant to traditional antibiotics, are the cause of severe problems like Hospital-Acquired Infections and sepsis. Reducing both time and costs for identification of these subspecies, thus diagnosing more efficiently infectious diseases, is crucial for our health systems. Current solutions in the field are based on expensive and time-consuming methods, and the fast, cost-efficient existing technologies, like MALDI-TOF MS, are restricted to the identification of main bacterial species, but are unable to go down to the subspecies level. Clover Biosoft is leveraging the power of modern AI techniques to develop algorithms using MALDI-TOF MS data to successfully classify bacterial subspecies.
Ours is a collaborative project assisted by several first-level public hospitals and cutting-edge scientists from various European universities. Time-to-market is essential, and the market is ripe for our solution. MALDI-TOF MS instruments have become a standard in microbiology laboratories worldwide, allowing a very easy integration with our software. Moreover, the increasing number of patients affected by HAIs and the growing resistance to antibiotics, have raised the public concern, becoming a priority now for public and private health system managers and governments.
Clover Biosoft is the ideal player to take this solution to the market, because of our long experience in the field and our extensive network, including all relevant type of stakeholders, from hospitals to big vendor companies and from researchers to government officials. Our team has the perfect combination of technical prowess, scientific background and business acumen. Our company has obtained solid revenues from its inception. Combining public and private investment, we are confident to take this project to market and become a reference for clinical diagnosis software development, bringing wealth and work to our region.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences infectious diseases
- natural sciences computer and information sciences software software development
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- natural sciences chemical sciences analytical chemistry mass spectrometry
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
18016 Granada
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.